Dark Streaming/Mobile Old Site Home Daily Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:44:55 EDT Thu 23 Mar 2023
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:OCX from 2022-03-24 to 2023-03-23 - 30 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2023-03-15 16:01U:OCXNews ReleaseOncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results
2023-03-02 09:00U:OCXNews ReleaseOncocyte Appoints Joshua Riggs as President and Chief Executive Officer
2023-02-22 08:00U:OCXNews ReleaseOncocyte Completes Razor Genomics Transaction
2022-12-16 08:00U:OCXNews ReleaseOncocyte Announces Initiatives to Focus Corporate Strategy
2022-11-30 18:05U:OCXNews ReleaseOncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors
2022-11-30 18:00U:OCXNews ReleaseOncocyte Announces Executive Leadership Changes
2022-11-10 16:30U:OCXNews ReleaseOncocyte Reports Third Quarter 2022 Financial Results
2022-10-27 16:01U:OCXNews ReleaseOncocyte to Announce Third Quarter 2022 Financial Results
2022-10-06 08:00U:OCXNews ReleaseDetermaIO(TM) Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer
2022-09-07 08:00U:OCXNews ReleaseOncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS
2022-08-31 16:01U:OCXNews ReleaseOncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference
2022-08-30 16:28U:OCXNews ReleaseOncocyte Announces Five-Year VA Contract for DetermaRx
2022-08-24 08:00U:OCXNews ReleaseOncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer
2022-08-10 16:05U:OCXNews ReleaseOncocyte Reports Second Quarter 2022 Financial Results
2022-08-03 16:01U:OCXNews ReleaseOncocyte to Participate at Upcoming Investor Conferences
2022-08-01 05:00U:OCXNews ReleaseOncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022
2022-07-27 16:01U:OCXNews ReleaseOncocyte to Announce Second Quarter 2022 Financial Results
2022-07-13 08:00U:OCXNews ReleaseOncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business
2022-07-06 08:00U:OCXNews ReleaseOncocyte Presents DetermaIO(TM) Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022
2022-06-22 08:00U:OCXNews ReleaseOncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice
2022-05-26 17:00U:OCXNews ReleaseOncocyte Presents DetermaIO(TM) Data at ASCO 2022 Supporting the Test's Potential to Expand the Clinical Use of Immunotherapy
2022-05-11 16:05U:OCXNews ReleaseOncocyte Reports First Quarter 2022 Financial Results
2022-05-05 08:00U:OCXNews ReleaseOncocyte Completes Validation of TheraSure(TM) Transplant Monitor Test
2022-04-28 16:01U:OCXNews ReleaseOncocyte to Announce First Quarter 2022 Financial Results
2022-04-27 16:30U:OCXNews ReleaseOncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO(TM)
2022-04-13 22:02U:OCXNews ReleaseOncocyte Corporation Announces Pricing of Public Offering of Common Stock and Warrants
2022-04-13 17:12U:OCXNews ReleaseOncocyte Corporation Announces Proposed Public Offering of Common Stock and Warrants
2022-04-13 17:10U:OCXNews ReleaseOncocyte Corporation Announces Pricing of Registered Direct Offering of 11,765 Shares of Series A Convertible Preferred Stock
2022-04-11 08:00U:OCXNews ReleaseOncocyte Presents Confirmatory Data for DetermaIO(TM) at the American Association for Cancer Research Annual Meeting 2022
2022-03-28 08:00U:OCXNews ReleaseOncocyte to Present New Data Confirming Association of IO Score with Response to Immunotherapy Treatment for Bladder Cancer at the American Association for Cancer Research Annual Meeting 2022